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Abstract
Background: There is no optimal screening tool for the assessment of pulmonary arterial
hypertension (PAH) in patients with systemic sclerosis (SSc). A decreasing transfer factor of the
lung for CO (TLCO) is associated with the development of PAH in SSc. TLCO can be partitioned
into the diffusion of the alveolar capillary membrane (Dm) and the capillary blood volume (Vc). The
use of the partitioned diffusion to detect PAH in SSc is not well established yet. This study evaluates
whether Dm and Vc could be candidates for further study of the use for screening for PAH in SSc.
Methods: Eleven SSc patients with PAH (SScPAH+), 13 SSc patients without PAH (SScPAH-) and
10 healthy control subjects were included. Pulmonary function testing took place at diagnosis of
PAH. TLCO was partitioned according to Roughton and Forster. As pulmonary fibrosis in SSc
influences values of the (partitioned) TLCO, these were adjusted for fibrosis score as assessed on
HRCT.
Results: TLCO as percentage of predicted (%) was lower in SScPAH+ than in SScPAH- (41 ± 7%
vs. 63 ± 12%, p < 0.0001, respectively). Dm% in SScPAH+ was decreased as compared with
SScPAH- (22 ± 6% vs. 39 ± 12%, p < 0.0001, respectively), also after adjustment for total fibrosis
score (before adjustment: B = 17.5, 95% CI 9.0–25.9, p = < 0.0001; after adjustment: B = 14.3, 95%
CI 6.0–21.7, p = 0.008). No difference was found in Vc%. There were no correlations between
pulmonary hemodynamic parameters and Dm% in the PAH groups.
Conclusion: SScPAH+ patients have lower Dm% than SScPAH- patients. There are no
correlations between Dm% and hemodynamic parameters of PAH in SScPAH+. These findings do
not support further study of the role of partitioning TLCO in the diagnostic work- up for PAH in
SSc.
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Systemic sclerosis (SSc) is an autoimmune disease charac-
terised by degenerative and fibrotic changes of skin, vascu-
lature and internal organs. Based on the extent of skin
thickening, patients are classified in either limited cutane-
ous SSc (LcSSc) or diffuse cutaneous SSc (DcSSc)[1]. In
general, patients with LcSSc are at higher risk of pulmo-
nary arterial hypertension (PAH), which is the leading
cause of death in this group of patients[2,3]. SScPAH
patients have a poor prognosis with a 3-year survival rate
of 50% despite therapy [4,5]. As therapeutic intervention
implemented at an earlier phase might modify the disease
course in SScPAH, new tools that assess PAH in patients
with SSc are warranted[6].
In this study we evaluate whether the components of the
transfer factor of the lung for carbonmonoxide (TLCO),
the conductance of the alveolar capillary membrane (Dm)
and the pulmonary capillary blood volume (Vc) as
assessed by the Roughton-Forster method [7], could be
candidates for further studies in the search for tools for the
diagnostic work-up for PAH in SSc patients. The TLCO is
reduced in patients with pulmonary arterial hypertension
(PAH) to generally 65%–72% of predicted [8-12]. In
patients with LcSSc, TLCO is reduced to an average of 40%
of predicted at the time of diagnosing PAH, and TLCO val-
ues of less than 50% of predicted have been detected in
patients with LcSSc without interstitial fibrosis 4.5 years
before PAH was diagnosed[2,13]. However, TLCO has not
been established yet as a marker for SScPAH. It remains to
be elucidated how interstitial lung disease influences
TLCO in these patients as severe interstitial lung disease
(defined by VC <70%) was excluded from these studies,
although a decrease in TLCO in combined restrictive lung
disease and pulmonary hypertension in SSc as compared
with isolated pulmonary hypertension in SSc has been
suggested [14]. Moreover, Mukerjee et al. demonstrated
only a weak correlation between mPpa and TLCO in SSc
patients [15]. The components of the partitioned TLCO,
however, might demonstrate (proportional) changes in
SSc patients with PAH as compared with SSc patients
without PAH. As patterns of Dm and Vc have not been
evaluated in these patient groups before, we compared
TLCO, Dm and Vc between SSc patients with PAH
(SScPAH+) and SSc patients without PAH (SScPAH-). We
also investigated the relation between the two compo-
nents of TLCO and PAH, by calculating correlations
between Dm and Vc and hemodynamic parameters
obtained during right heart catheterisation.
Methods
Patient population
Systemic sclerosis patients with PAH (SScPAH +) and
without PAH (SScPAH-) attending the outpatient clinic of
the VU University medical center between February 2004
and December 2006 were identified. Patient charts were
reviewed from February 2004 onward, as since that date
partitioned membrane diffusion measurements were con-
sistently implemented according to the method described
below.
In the SScPAH+ group, patients were included if they had
undergone pulmonary function testing according to the
method described below and an HRCT scan one day
before diagnosis of PAH. PAH was diagnosed at a mean
pulmonary artery pressure (mPpa) of ≥ 25 mmHg, a pul-
monary capillary wedge pressure (PCWP) of < 15 mmHg,
and a pulmonary vascular resistance of > 240
dynes·s·cm-5 measured by right heart catheterization.
In the SScPAH- group, PAH was excluded by means of
right heart catheterization or a systolic Ppa < 30 mmHg
estimated from the tricuspid regurgitation jet[15].
Patients were excluded if they had clinical or echocardio-
graphic signs of left ventricular heart disease. Pulmonary
function testing in this group had to be performed within
1 day of right heart catheterisation or echocardiography. A
time lapse of 6 months between pulmonary function test-
ing and HRCT scan was accepted. SSc was classified
according to the LeRoy classification system[1]. Ten
healthy, non-smoking persons underwent pulmonary
function testing to form a control group for TLCO, Dm
and Vc measurements.
Pulmonary function
Static and dynamic lung volumes
Forced expiratory flow in 1 s (FEV1), forced vital capacity
(FVC), vital capacity (VC) and total lung capacity (TLC)
were assessed with standard pulmonary function test
equipment ( max 22 and 6200, Sensor Medics, Yorba
Linda, CA, U.S.A.). Measurements were performed
according to ERS guidelines[16].
TLCO measurement
TLCO was measured by single-breath method breathing
room air of 21% O2 and a gas mixture of 0.3% carbon
monoxide (CO), 0.3% methane (CH4), 21% oxygen (O2)
balanced with nitrogen (N2) starting at residual volume to
TLC followed by a ten seconds breath hold meeting ERS
guidelines [16].
Determination of Dm and Vc
Dm and Vc and were measured at different alveolar oxy-
gen concentrations. All measurements were performed in
duplicate. The linearity of the relation using four different
oxygen concentrations (21%, 40%, 60% and 80%) under
our experimental conditions was verified in a group of 8
healthy controls and 10 patients with pulmonary arterial
hypertension. Moreover, the sensitivity of Vc measure-
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and supine position according to [17](data not shown).
The first manoeuvre was performed as described above,
after breathing room air. The second manoeuvre took
place after breathing 60% O2 for five minutes, immedi-
ately followed by the single breath measurement with a
gas mixture of 0.3% carbon monoxide (CO), 0.3% meth-
ane (CH4), 60 % oxygen (O2) balanced with nitrogen
(N2).
Dm and Vc were calculated according to the Roughton-
Forster equation: [7]
1/TLCO = 1/DmCO+ 1/θCO*Vc
where θCO is the rate of reaction of CO with hemoglobin
(Hb) and1/θ is the specific transfer resistance from the red
cell membrane to the haemoglobin molecule.
θ is determined by the following equation: (α + β * PAO2)
* [Hbst/Hb], where α = 0.001 and β = 0.000134 and
[Hbst/Hb] is a standardised normal Hb value divided by
the haemoglobin concentration of the patient [18]. For
PAO2, a value of 13.21 mmHg was used, derived from the
alveolar gas equation[19].
By the mean of the two values of TLCO measured at each
alveolar O2 concentration and θ, a plot of 1/TLCO against
1/θ is obtained. 1/Dm is given by the y-intercept and 1/Vc
is given by the slope of the straight line.
We utilised reference equations described by Zanen et
al[20], as they applied a technique that is similar to ours
and because their equations have lower standard devia-
tions (while showing similar relationships between
height, age and 1/Vc and 1/DmCO) than previous studies.
After calculating the 95% confidence interval (CI), meas-
ured values obtained in normal subjects in our laboratory
are within the normal range (data not shown). The repro-
ducibility of the technique is regularly assessed in our lab-
oratory.
Dm and Vc values outside the 95% CI, calculated with the
reference equations using parameters height, age and gen-
der, and the reference equation's standard deviations,
were considered abnormal. For the evaluation of the pro-
portionality of change of Dm in respect to Vc, the Dm%/
Vc% ratio, with both values presented as percentages of
predicted, was calculated. A disproportionate reduction of
Dm relative to Vc is indicated by a ratio less than 1[21].
Analysis of hemodynamic parameters
Pulmonary capillary wedge pressure (PCWP) was meas-
ured in order to exclude left sided heart disease and calcu-
late pulmonary vascular resistance (PVR). Cardiac output
(CO) was calculated by the Fick method and PVR was cal-
culated by (mPpa – PCWP)/CO.
HRCT
As interstitial fibrosis is a known feature in LcSSc [22]
affecting Dm and Vc, interstitial fibrosis was evaluated by
means of HRCT. HRCT had to be performed within 6
months of lung function testing. All HRCTs consisted of
1.0 mm thick sections taken at 1 cm intervals throughout
the entire thorax (CT Sensation 64; Siemens; Erlangen;
Germany). No intravenous contrast was administered.
Three independent readers scored reticular opacity and
ground glass on a scale of 0–5 for each lobe, with a maxi-
mum of 50, according to the scoring system described by
Kazerooni et al. [23]. These scores were also added and are
reported as the total fibrosis score [24].
Statistical analysis
SPSS 12.0 software package (Chicago, IL) was used for sta-
tistical analyses, and p < 0.05 was considered statistically
significant. Normal distribution was evaluated by Sha-
piro-Wilkinson's test. One-way analysis of variance was
performed for comparisons between groups. Because of
multiple testing the threshold for significance was
adjusted using the Bonferroni correction for families of
tests. Student t test was used for comparison of HRCT
fibrosis scores and haemodynamics parameters between
the SScPAH+ group and (the catheterised patients from)
the SScPAH- group. Values in tables are expressed as mean
± SD, and in figures as mean ± SE.
As Dm is influenced by fibrosis, correction for fibrosis was
performed by multiple regression, where Dm was the
dependent variable, and disease type and total fibrosis
were the independent variables. The relation between
hemodynamic parameters and Dm or Vc was determined
by using the Pearson's correlation coefficient.
Results
Patient population
Twenty-four patients were included, 11 SScPAH+ patients
and13 SScPAH- patients. Patient characteristics are shown
in Table 1. The mean age of the SScPAH+ patients neither
differed significantly from the SScPAH- patients nor from
the control subjects. All SSc patients suffered from the lim-
ited cutaneous form of the disease. Height and gender
were similar in the groups. SScPAH+ patients and
SScPAH- were similar with respect to SSc classification
and modified Rodnan skin score. Duration of Raynaud
symptoms at diagnosis of SSc was significantly longer in
the SScPAH+ group than in the SScPAH- group (p =
0.009).
Six out of 13 patients of the SScPAH- group had under-
gone right heart catheterisation. The SScPAH + patientsPage 3 of 8
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of 6 catheterised SScPAH- patients. All patients had a
SaO2 of > 92% and higher. The total score of fibrosis and
ground glass did not differ between the SScPAH+ and
SScPAH- group.
Pulmonary function testing
Results of pulmonary function testing are outlined in
Table 2. No signs of either obstructive or restrictive airway
disease were found in the patient groups (Table 2). TLCO
was impaired in both patient groups as compared with
controls. SScPAH+ patients had significantly lower
TLCO% values than SScPAH- (p < 0.0001) (Figure 1A). All
SScPAH+ and SScPAH- patients had reduced Dm%. Dm%
values in SScPAH+ patients were significantly lower than
in the SScPAH- group (Figure 1B), also after adjustment
for total fibrosis score (before adjustment: B = 17.5, 95%
CI 9.0–25.9, p = < 0.0001; after adjustment: B = 14.3, 95%
CI 6.0–21.7, p = 0.008). Figure 1 demonstrates overlap of
Dm% values between the SScPAH+ and SScPAH- groups,
a finding also observable for TLCO%.
Table 1: Demographic data
SScPAH+ N = 11 SScPAH- N = 13 Control N = 10
Age, yr 70.1 ± 9.6 66.2 ± 11.2 59.7 ± 6.5
Height, m 1.6 ± 0.1 1.7 ± 0.1 1.7 ± 0.1
Male/Female 0/9 0/12 2/8
Limited cutaneous SSc (%) 100 100
Haemoglobin, mmol/l 7.8 ± 1.2† 8.0 ± 0.6‡ 8.6 ± 0.8
Raynaud's phenomenon (%) 100 92
Raynaud's phenomenon at PFT, years 19.2 ± 10.6* 6.6 ± 8.3
Autoantibodies (no.) 12
ANA 10 6
Anti-centromere 7 5
Anti-topoisomerase 0
Modified Rodnan skin score 14.1 ± 5.7 11.9 ± 5.9
Smoking status 7/3/1 6/4/2 8/2/0
Never/former/current (no.)
6-minute walking distance, m 326 ± 102 430 ± 127
SvO2, % 62.7 ± 6.6* 72.5 ± 2.0
HRCT fibrosis score‡ 4.9 ± 3.4† 4.1 ± 3.4
HRCT ground glass score‡ 7.1 ± 5.8† 3.1 ± 5.5
HRCT total fibrosis score‡ 12.1 ± 6.8† 7.4 ± 8.5
Values expressed as mean ± SD, otherwise as stated. Abbreviations: SScPAH+: systemic sclerosis associated pulmonary arterial hypertension. 
SScPAH-: SSc without PAH;. PFT: pulmonary function testing; ANA: anti-nucleolar antibodies.. SvO2: mixed venous oxygen saturation. * p < 0.05 
for comparison of SScPAH+ with SScPAH-; † According to reference 23. ‡ According to reference 24.
Table 2: Static and dynamic lung volumes
SScPAH+ N = 11 SScPAH- N = 13 Control N = 10
FVC, % pred 97.5 ± 20.8† 103.0 ± 22.4 122.1 ± 17.0
FEV1, % pred 83.5 ± 12.1† 92.5 ± 20.4 108 ± 12.4
FEV1/VC 69.4 ± 9.8 72.8 ± 7.0 74.2 ± 6.3
TLC, % pred 90.3 ± 17.1 91.4 ± 13.6
TLCO, % pred 40.7 ± 6.8* † 63.3 ± 11.7‡ 93.3 ± 15.0
Dm, mmol·min-1·kPA-1 3.7 ± 1.1* † 7.5 ± 2.8‡ 15.1 ± 4.1
Dm,% pred 21.7 ± 5.8* † 39.2 ± 12.4‡ 81.3 ± 18.0
Vc, ml 40.2 ± 14.30 45.8 ± 13.7 56.2 ± 16.1
Vc, % pred 59.9 ± 24.6† 61.7 ± 17.6‡ 82.8 ± 10.8
Dm%/Vc % 0.41 ± 0.25† 0.71 ± 0.37 1.00 ± 0.26
Vc%/Dm % 2.99 ± 1.5* † 1.73 ± 0.74 1.06 ± 0.26
Values expressed as mean ± SD. Abbreviations: SScPAH+: systemic sclerosis-associated pulmonary arterial hypertension; SScPAH-: SSc without 
PAH. FEV1 %: forced expiratory volume, percentage of predicted. TLC: total long capacity. TLCO: transfer factor of the lung for carbon monoxide. 
Dm: diffusing capacity of the alveolar capillary membrane. Vc: pulmonary capillary volume. * p < 0.05 for comparison of SScPAH+ with SScPAH-; † p 
< 0.05 for comparison of SScPAH+ with control.‡ p < 0.05 for comparison of SScPAH- with controlPage 4 of 8
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compared with the control group,, however, between the
patient groups there was no significant difference. The
Vc%/Dm% ratio was significantly higher in SScPAH+ as
compared with SScPAH- and controls (p = 0.01 and p = <
0.0001). These values also demonstrated overlap between
the groups (Figure 2).
Relationship between pulmonary and cardiovascular 
function
Hemodynamic data resulting from right heart catheterisa-
tion are shown in table 3.
No significant correlations between TLCO%, Dm%, Vc%
and mPpa, PVR, SvO2 and PAH- prognostic parameters
such as CI and mean right atrial pressure [10], were found,
nor for the Dm%/Vc% or Vc%/Dm% ratios and those
hemodynamic parameters. The relation between Vc%/
Dm% and PVR and mPpa is illustrated in figure 3.
Discussion
Dm and Vc in SScPAH+
In the present study we have shown that the Dm compo-
nent is the principal contributor to the reduction in TLCO
in SSc patients with PAH, as reflected by the Dm%/Vc%
ratio < 1. Reduction of both Dm% and Vc% in this group
can be ascribed to various pathophysiologic mechanisms.
Firstly, vascular obliteration as occurs in PAH results in a
decrease in capillary flow and thus a decrease in Vc. This
will result in a reduction in surface area available for gas
exchange, and therefore in a decrease of Dm [25]. Sec-
ondly, parenchymal and vascular destruction in areas of
fibrosis can contribute to the reduction of Dm and
Vc[26,27], although in this study none of the patients suf-
fered from severe fibrosis on HRCT. However, such con-
clusions should be drawn cautiously as the relation
between TLCO and HRCT findings in SSc is weak [28].
Finally, effects of abnormalities in haemorheology on Dm
might play a role. It has been demonstrated experimen-
tally that non-uniform distribution or deformation of
erythrocytes within a capillary segment affect Dm[29];
disturbed haemorheology has been shown in SSc[30].
Dm and Vc in SScPAH+ compared with SScPAH-
Dm% in SScPAH+ was significantly lower as compared
with SScPAH-. This difference could not be ascribed to fac-
tors affecting Dm such as age, height and gen-
der[20,31,32]. All SSc patients had some degree of
fibrosis, a known phenomenon in the limited cutaneous
form of SSc[22]. However, the difference in Dm% was
maintained after correction for interstitial fibrosis. There-
fore, it may be concluded that pulmonary vascular dam-
age is the primary contributor of the decrease in Dm.
However, there were no indications that Dm was a supe-
rior discriminator than TLCO between the groups.
The lower Dm% in the SScPAH+ group could occur due to
the vessel obliteration in PAH. When only considering the
abnormal Dm% values of the SScPAH- group, these can
be explained by interstitial lung disease and/or abnormal
haemorheology. In addition, it cannot be excluded that
some of these patients had latent pulmonary vessel dis-
ease [33]. Vascular injury features in SSc pathogenesis in
general, and also underlies the development of interstitial
lung disease[34,35]. This may also explain the absence of
a difference in Vc between SScPAH + and SScPAH-.
Recruitment of remaining vasculature in SScPAH+ might
also play a role in the similar Vc values compared with
SScPAH-, however, there are no studies on vessel recruit-
ment in SScPAH.
Despite these suggestions, it is difficult to completely
explain the underlying mechanisms of our findings. The
Roughton-Forster equation assumes that 1/TLCO is the
sum of two resistances representing either alveolocapil-
lary wall disease (Dm) or abnormalities on the vascular
level (Vc). However, Dm and Vc may not act as independ-
ent entities. Decrease in capillary flow, affecting Vc, result
in reduction in surface area in affected tissue and therefore
in a decrease of Dm[25]. Moreover, this decrease in Dm
due to decrease in Vc could be disproportional as is shown
by a mathematical model[21]. Irregular perfusion in pul-
monary vascular disease [36,37], which is a result of the
distension of remaining vasculature in reaction to curtail-
ment of pulmonary vessels in PAH and/or fibrosis, may
also result in unpredictable behaviour of Dm and Vc.
A. The transfer factor of the lung for carbonmonoxide (TLCO%) i  patien s with systemic sclerosis-associated pul-monary arterial hypertension (SScPAH+) and in patients with systemic sclerosis with u  PAH (SScPAH-)Figur 1
A. The transfer factor of the lung for carbonmonox-
ide (TLCO%) in patients with systemic sclerosis-asso-
ciated pulmonary arterial hypertension (SScPAH+) 
and in patients with systemic sclerosis without PAH 
(SScPAH-). B. The diffusion capacity of the alveolar 
capillary membrane as percentage of predicted 
(Dm%) in SScPAH+ and SScPAH-. Mean and SE are 
shown.
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and Dm and Vc values
No relations between hemodynamic parameters of pul-
monary hypertension and Dm or Vc were found. Correla-
tions between hemodynamic values and the two
components of TLCO have been reported scarcely. Steen-
huis et al. found an association between absolute Dm and
PVR in patients with IPAH (r = 0.54, p = 0.04), which dis-
appeared when using the predicted value of Dm [11].
Others showed an inverse relationship between mPpa and
Vc in a group with miscellaneous forms of PAH, whereas
they did not find the correlation between Dm and mPpa
[21]. Bonay et al. showed a relationship between Vc/Dm
ratio and systolic Ppa values in patients with chronic infil-
trative lung disease[27]. Although in our study these val-
ues differed significantly between the groups, no such a
relationship was found. We also performed measure-
ments of Dm and Vc in a group of 14 patients with idio-
pathic PAH (IPAH) [see Additional file 1]; we did not find
any relation between Dm, Vc, or their ratios and hemody-
namic parameters in this PAH population either. Taken
together, these findings limit the clinical value of parti-
tioning TLCO in SSc and SScPAH.
A limitation of this study is the small patient number.
Methodological limitations include the acquisition of the
Dm component that might be prone to inaccurateness: a
small change of the slope of the 1/TLCO-1/θ line can lead
to a large change at the y-intercept that determines Dm.
However, we believe that this leads to a systematic error
without consequences for the proportionality of the val-
ues between the patient groups. We used two different
oxygen concentrations for the determination of TLCO as
has been used by others as well[11,20,21,27,31,38,39];
the linearity of the slope was verified in our experimental
conditions using four oxygen concentrations. Moreover,
to maximize preciseness, we performed duplicate meas-
urements. One SScPAH+ and two SScPAH- patients were
current smokers, although not heavily, and as such a pos-
sible elevated HbCO might have influenced TLCO meas-
urements. Six out of 13 patients from the SScPAH- group
were not catheterised. However, on echocardiography,
these patients did not demonstrate (signs of) elevated
right ventricular afterload. All SSc patients were suffering
from the limited cutaneous form, which can be consid-
ered as a limitation, as patients with the diffuse form
belong to the group with more risk on pulmonary fibrosis
with subsequent pulmonary hypertension. Classically,
pulmonary hypertension has been considered as an iso-
lated pulmonary vasculopathy in the group of SSc patients
with longstanding limited cutaneous form. However, all
our patients had some fibrosis on HRCT, an observation
which has been recognized by others as well [40].
Conclusion
Altogether we demonstrated that the lower TLCO in
SScPAH+ patients as compared with SScPAH- patients is
attributable to the lower Dm in SScPAH+ patients. How-
ever, explanations of pathophysiologic mechanisms are
speculative. Moreover, we did not find correlations with
hemodynamic parameters of SScPAH. Based on these con-
siderations, we do not support further research for the role
of the partitioned TLCO in the diagnostic work-up for pul-
monary hypertension in SSc patients.
The ratio of the pulmonary capillary blood volume as per-centage f predicted and the diffusion capacity of the alv olar apillary membrane as pe c ntage f predi ted (Vc%/Dm%) in ati nts with systemic s lerosi -ass ci ted pulmonary art ri l hyper ension (SScPAH+) and t en s with syst mic scl osis without PAH (SS PAH-)Figu 2
The ratio of the pulmonary capillary blood volume as 
percentage of predicted and the diffusion capacity of 
the alveolar capillary membrane as percentage of 
predicted (Vc%/Dm%) in patients with systemic scle-
rosis -associated pulmonary arterial hypertension 
(SScPAH+) and patients with systemic sclerosis with-
out PAH (SScPAH-). Mean and SE are shown.
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Table 3: Hemodynamic parameters
SScPAH+ N = 11 SScPAH- N = 6
mPra, mmHg 4.5 ± 1.8 2.8 ± 2.2
mPpa, mmHg 36.7 ± 5.7* 18.0 ± 2.4
PVR, dynes/s·m5 625 ± 218* 117 ± 28
PCWP, mmHg 8.7 ± 4.0 7.8 ± 3.8
CI, l/m2 2.3 ± 0.3* 3.4 ± 0.9
Values expressed as mean ± SD. Definition of abbreviations: 
SScPAH+: systemic sclerosis-associated pulmonary arterial 
hypertension; SScPAH-: SSc without PAH. mPra: mean right atrial 
pressure; Ppa: pulmonary artery pressure; PVR: pulmonary vascular 
resistance; CI: cardiac index; PCWP: pulmonary capillary wedge 
pressure.* p < 0.05 for comparison of SScPAH+ with SScPAH-;Page 6 of 8
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6 MWD: six minute walking distance; Dm: diffusion of the
alveolar capillary membrane; HRCT: high resolution com-
puted tompography; IPAH: idiopathic pulmonary arterial
hypertension; PAH: pulmonary arterial hypertension;
Ppa: pulmonary artery pressure; PCWP: pulmonary capil-
lary wedge pressure; SSc: systemic sclerosis; SScPAH: sys-
temic sclerosis-associated pulmonary arterial
hypertension; TLC: total lung capacity; TLCO: diffusion
capacity of the lung for carbon monoxide; Vc: pulmonary
capillary blood volume.
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